These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1371 related items for PubMed ID: 15871628

  • 1. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R.
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [Abstract] [Full Text] [Related]

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE.
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D, Indolfi P, Galderisi M, Bossone E.
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 7. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR, Spencer CM.
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [Abstract] [Full Text] [Related]

  • 8. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI, Lipshultz SE.
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [Abstract] [Full Text] [Related]

  • 9. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
    Elbl L, Hrstkova H, Tomaskova I, Michalek J.
    Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
    [Abstract] [Full Text] [Related]

  • 10. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS, Scott LJ.
    Drugs; 2005 Feb; 65(7):1005-24. PubMed ID: 15892593
    [Abstract] [Full Text] [Related]

  • 11. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S, Bhatia S.
    Am Soc Clin Oncol Educ Book; 2018 May 23; 38():3-12. PubMed ID: 30231396
    [Abstract] [Full Text] [Related]

  • 12. [Anthracyclines and the heart].
    Mazzarello GP, Morra L.
    Recenti Prog Med; 1998 Sep 23; 89(9):459-64. PubMed ID: 9796378
    [Abstract] [Full Text] [Related]

  • 13. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E, Mastroiacovo G, Lupieri A, Frati G, Peruzzi M.
    Adv Exp Med Biol; 2017 Sep 23; 1000():103-129. PubMed ID: 29098619
    [Abstract] [Full Text] [Related]

  • 14. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S, Wojnowski L.
    Cardiovasc Toxicol; 2007 Sep 23; 7(2):129-34. PubMed ID: 17652817
    [Abstract] [Full Text] [Related]

  • 15. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
    Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Roh J, Šimůnek T, Štěrba M.
    J Pharmacol Exp Ther; 2020 Jun 23; 373(3):402-415. PubMed ID: 32253261
    [Abstract] [Full Text] [Related]

  • 16. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B.
    Pediatr Blood Cancer; 2005 Jun 15; 44(7):584-8. PubMed ID: 15700251
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy-induced cardiotoxicity in children.
    Bansal N, Amdani S, Lipshultz ER, Lipshultz SE.
    Expert Opin Drug Metab Toxicol; 2017 Aug 15; 13(8):817-832. PubMed ID: 28679288
    [Abstract] [Full Text] [Related]

  • 18. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M, Duarte-Rodrigues J, Campelo M.
    Rev Port Cardiol; 2016 Jun 15; 35(6):359-71. PubMed ID: 27255173
    [Abstract] [Full Text] [Related]

  • 19. Prevention of Chemotherapy Induced Cardiomyopathy.
    Payne DL, Nohria A.
    Curr Heart Fail Rep; 2017 Oct 15; 14(5):398-403. PubMed ID: 28779279
    [Abstract] [Full Text] [Related]

  • 20. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA, Lipshultz SE.
    Semin Oncol; 1998 Aug 15; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.